Ribo Receives Granted Patents for Phase 2 HBV siRNA Asset RBD1016 in United States and Europe
Ribocure Pharmaceuticals/Suzhou Ribo Life Science Co. Ltd. (“Ribo”) announce Notice of Allowance issued respectively by US Patent Office and European Patent Office for patent applications covering the anti-hepatitis B siRNA drug RBD1016. With the approved patents in US and Europe, and with the previous authorizations in six major countries/regions, including China and Japan, Ribo’s strategy […]
Ribo & Ribocure successfully completed enrolment and dosing in the Phase 1 clinical trial, with world’s first siRNA drug targeting coagulation factor XI (FXI)
On April 10, 2024, Ribo and Ribocure announce the completion of enrolment and dosing of the Ph1 clinical trial with world’s first and most advanced anti-thrombotic siRNA drug, RBD4059, targeting coagulation factor XI (FXI). The Phase I clinical trial is a randomized, single-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics, and potency of RBD4059 […]
Innovating for a Healthier Tomorrow: Ribocure’s Role in Transforming Liver Disease Treatment with siRNA
Ribocure Pharmaceuticals AB announces EMA authorisation to proceed with a Phase II clinical trial in Sweden. The trial will evaluate the efficacy and safety of its novel siRNA asset RBD1016, for the treatment of the rare disease of chronic hepatitis D infection. Ribocure Pharmaceuticals AB, the international research center of Suzhou Ribo Life Science Ltd, […]
Ribocure supports WORLD KIDNEY DAY on March 14th
Ribocure Pharmaceuticals AB is a clinical stage biotech company developing oligonucleotide-based therapeutics (siRNA). Across the globe, chronic kidney disease (CKD) affects around 700 million people, with 3.1 million deaths attributable to kidney dysfunction, making it the seventh leading cause of mortality worldwide. Low- and middle-income countries bear a disproportionate burden of CKD and kidney failure. Multiple […]
Ribocure supports RARE DISEASE DAY on February 29th
Ribocure Pharmaceuticals AB is a clinical stage biotech company developing oligonucleotide-based therapeutics (siRNA). Our primary focus lies in addressing unmet medical needs in rare diseases by using precision medicine approaches. We are working on several disease areas that include HDV infection, chylomicronemia syndrome (patients with extremely high triglyceride levels and suffering from frequent pancreatitis), as […]
Ribo partners with Boehringer Ingelheim to develop new treatments for people with liver diseases
Mölndal, Sweden, Kunshan, China and Ingelheim, Germany – 3 January 2024 Suzhou Ribo Life Science Co. Ltd. and Ribocure Pharmaceuticals AB (Ribo) today announced a collaboration with Boehringer Ingelheim to develop novel treatments for nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH). The partnership brings together Ribo’s leading experience in the discovery and clinical development of small […]
Portrait of Li-ming Gan in GoCo News
Our CEO has been portrayed in GoCo news. Here he shared his views on how productive collaboration between industry, academia and health sector may contribute to a successful Swedish life science sector. Read the full article here.
Ribocure Clinic marks milestone with first patient enrolled in a deep phenotyping clinical study
With the ambition to become the leading clinical oligonucleotide research company in Sweden, Ribocure Pharmaceuticals AB established Ribocure Clinic, with a vision to drive excellence in proof of principle/concept clinical trials with an in-house high volume and high quality Ph2 clinical trial unit. Now the first patient has been enrolled in a deep phenotyping study […]
Ribocure Pharmaceuticals and Ribo Life Science announce appointment of John Taylor to Vice President, Head of Global Business Development
John Taylor has joined Ribocure Pharmaceuticals AB as Vice President and Head of Global Business Development. John will lead the global BD team and oversee partnering discussions for Ribocure Pharmaceuticals AB, as well as its parent company Ribo Life Sciences (Ribo) to support its externalization. Li Ming Gan, Ribocure’s CEO and Co-CEO for Ribo said: […]
Ribo announces the latest research news for three siRNA therapeutic drugs at the European Society of Cardiology Congress 2023
Suzhou Ribo Life Science (Ribo) and Ribocure Pharmaceuticals (Ribocure) presented new data from three projects from its cardiovascular pipeline at the European Society of Cardiology Congress (ESC) in Amsterdam on August 25-28, the world’s largest and most influential conference in cardiology. Building on its proprietary liver-targeting platform RIBO-GalSTAR®, highly specific, potent and durable gene silencing […]
